Search results
Results from the WOW.Com Content Network
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and CRISPR Therapeutics wasn’t one of them. The 10 stocks that ...
CRISPR Therapeutics (NASDAQ: CRSP) isn't a stock that's wanting for reasons to invest. ... As of the most recent quarter, Q3, it reported having around $1.9 billion in cash, equivalents, and short ...
CRSP Market Cap data by YCharts. 3. Intensive competition. The success of CRISPR Therapeutics will depend on its ability to bring multiple new drugs to the market to support a more viable business ...
CRISPR Therapeutics has a $3.9 billion market cap at recent prices, but the stock is less expensive than it looks on the surface. With a big cash cushion and a lack of debt, its enterprise value ...
News. Science & Tech. Shopping. Sports. Weather. 24/7 Help. For premium support please call: 800-290-4726 more ways to reach us. Sign in. ... With that sunny setup, CRISPR's stock is an easy buy.
The news also pushed up stocks of companies making gene-editing drugs, FATE, CRSP, EDIT, using CRISPR technology. Skip to main content. 24/7 Help. For premium support please call: 800-290-4726 ...
CRISPR Therapeutics was founded in 2013 by Emmanuelle Charpentier, Shaun Foy and Rodger Novak. [6] Charpentier later shared the Nobel Prize in Chemistry in 2020 with Jennifer Doudna. As part of a working group, she provided the first scientific documentation on the development and use of CRISPR gene editing. This allows DNA to be specifically ...
CRISPR Therapeutics shares have crushed the market since its IPO, delivering an exceptional compound annual growth rate (CAGR) of 20.1%. A lot has changed since then.